Ascendis Pharma (ASND) could see a rise in consensus estimate following a promising launch of Yorvipath in hypoparathyroidism treatment, Morgan Stanley said in a note Monday.
"The first quarter of US Yorvipath performance through 1Q25 results was ~2x ahead of our expectations," the note said.
"While we acknowledge the launch remains early, initial metrics provide an encouraging read to provider appetite, prescription growth, and payor receptivity," the report added.
Morgan Stanley said it revised its Yorvipath estimates upwards to peak sales of over $2 billion.
The report said the launch metrics and commercial performance are aligning well with strong feedback, pointing to "potential for 2025 performance that can drive consensus higher."
Morgan Stanley upgraded Ascendis to overweight from equalweight and boosted its price target to $250 from $180.
Price: 173.85, Change: +1.79, Percent Change: +1.04
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。